A randomized double-blind, cross-over study using treatment periods of 12 weeks with a 2-week washout, comparing two long-acting formulations of propranolol (`Inderal’*(1) LA 160 mg daily and Half-‘Inderal’ LA 80 mg daily) was performed after a placebo run-in of 4 weeks on 51 patients. The study indicated that both long-acting formulations were significantly better than placebo in reducing the frequency of migraine attacks (p < 0.01). After 12 weeks there was a significantly lower (p = 0.03) frequency of migraine attacks in patients on the higher dose formulation than in those on the lower dose formulation. There was no significant difference in the frequency of side effects produced by the two formulations.
Get full access to this article
View all access options for this article.
References
1.
DiamondSKudrowLStevensJShapiroDB.Long-term study of propranolol in the treatment of migraine.Headache1982;22(6):268–71.
2.
McAinshJRoweRC.Sustained release pharmaceutical composition.United States Patent 41979,138, 475, February 4th.
3.
McAinshJBarberNSSmithRYoungJ.Pharmacokinetic and pharmacodynamic studies with long acting propranolol.Br J Clin Pharmacol1978;6:115–21.
4.
LeaheyWJNeillJDVarmaMPSShanksRG.Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.Br J Clin Pharmacol1980;9:33–40.
5.
McAinshJBaberNSHolmesBFYoungJEllisSH.Bioavailability of sustained release propranolol formulations.Biopharm Drug Disp1981;2:39–48.
6.
DrummerOHMcNeilJPritchardELouisWJ.Combined high-performance liquid chromatographic procedure for measuring 4-hydroxy-propranolol and propranolol in plasma. Pharmacokinetic measurements following conventional and slow-release propranolol administration.J Pharm Sci1981;70:1030–2.
7.
SerlinMJOrmeMLMaclverMGreenGJSibeonRGBreckenridgeAM.The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.Br J Clin Pharmacol1983;15:519–27.
8.
OhashiKEbiharaAKondoKUsamiM.Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.Arzneim Forsch1984;34:507–12.
9.
ZiamBKramlMDvornikDRyderGMullaneJF.‘Inderal’ LA: comparison of the profiles of plasma drug concentration/time curves produced in man by propranolol hydrochloride long-acting (80 and 60 mg) and atenolol (50 and 100 mg).Curr Ther Res1984;5:896–904.
10.
RavenscroftPJCharlesBGRenshawPJ.The bioavailability of propranolol and 4-hydroxy-propranolol: a comparison of conventional and long-acting preparations.Aust Soc Clin Exp Pharmacol1981,Adelaide, Abs 122.
11.
McAinshJGayMA.Theoretical Michaelis-Menten elimination model for propranolol.Eur J Drug Metab Pharmacokinet1985;10:241–5.
12.
.Ad hoc committee on classification of headache.Classification of headache.J Am Med Assoc1962;179:717–18.
13.
Havanka-KanniainenHHokkanenEMyllylaVV.Long-acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg.Headache1988;28:607–11.
14.
KuritzkyAHeringR.Prophylactic treatment of migraine with long acting propranolol-a comparison with placebo.Cephalalgia1987;7(6):457–8.
15.
Calderon-GonzalezR.Migraine in children.Compendium Invest Clin Latino Americas1981;1:27–30.
16.
GuerraRR.Prophylactic treatment of migraine with beta-adrenergic blockers.Semana Medical de Mexico1980;97:167–74.
17.
WeberRBReinmuthOM.The treatment of migraine with propranolol.Neurology1972;22:366–9.
18.
MalveaBPGwonNGrahamJR.Propranolol prophylaxis of migraine.Headache1973;12:163–7.
19.
LudvigssonJ.Propranolol treatment of migraine in children.Lancet1973;2:799.
20.
WideroeTEViganderT.Propranolol in the treatment of migraine.Br Med J1974;2:699–701.
21.
BorgesenSENielsenJLMollerCE.Propranolol in migraine.Lancet1974;2:58.
22.
DiamondSMedinaJL.Controlled study of the prophylaxis of migraine with propranolol.Clin Pharmacol Ther1975;17:232.
23.
ForssmanBHenrikssonKGJohanssonVLund-vailLLundinH.Propranolol for migraine prophylaxis.Headache1976;16:238–45.
24.
PitaEHiguerasABolanosJ.PerezNMundoA.Propranolol and migraine. A clinical trial.Arch Farmacol Toxicol1977;3:273–8.
25.
BernikVMaiaE.The use of propranolol in prophylaxis of migraine: A double-blind clinical trial comparing propranolol with an analgesic drug (acetominophen) and placebo.Folha Medica1978;77:501–8.
26.
PalfermanTGGibberdFBSimmondsJP.Prophylactic propranolol in the treatment of headache.Br J Clin Pract1983;37:28–9.
27.
DiamondS.Long term study of propranolol in the treatment of migraine.Headache1982;22:146Abstract.
28.
DiamondSKudrowLStevensJShapiroDB.Long-term study of propranolol in the treatment of migraine.Headache1982;22:268–71.
29.
StensrudPSjaastadO.Short term clinical trial of propranolol in racemic form (‘Inderal’), D-propranolol and placebo in migraine.Acta Neurol Scand1976;53:229–32.
